Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Lower Infections with Elranatamab in Multiple Myeloma in Real-World Settings | EHA 2026
HealthTreeDescription
Bispecific antibodies have transformed the treatment landscape for relapsed/refractory multiple myeloma, but infections remain a significant concern. At EHA 2026, Dr. Rahul Banerjee presented real-world data evaluating infection rates among patients receiving elranatamab outside of clinical trials.
The analysis explored how infection patterns observed in everyday clinical practice compare with those reported in clinical studies and identified factors that may contribute to lower infection rates.
If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu
For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.